FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285492011> ?p ?o ?g. }

• W4285492011 endingPage "1634" @default.
• W4285492011 startingPage "1621" @default.
• W4285492011 abstract "Sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors ameliorate blood glucose levels in patients with type 2 diabetes mellitus (T2DM) by inhibiting the reabsorption of glucose from the kidneys, thus increasing urinary glucose excretion. Most SGLT2 inhibitors have been reported to exert dose-dependent effects. However, little is known about the benefits of increasing the dose of SGLT2 inhibitors in clinical use. The aim of the present study was to investigate the effect of increasing the dose of the SGLT2 inhibitor empagliflozin in T2DM. We collected 52 subjects with T2DM with inadequate glycemic control. The dose of empagliflozin was increased from 10 to 25 mg, taken once daily, and the alterations in glycemic control and several other clinical parameters were evaluated. The increased dose of empagliflozin significantly ameliorated glycemic control. In addition, body weight (BW), body mass index (BMI), triglyceride (TG), and γ-glutamyltranspeptidase (GGT) were significantly decreased and hematocrit (Hct) was increased. Multivariate logistic regression analyses revealed that baseline diastolic blood pressure (DBP) (odds ratio 1.093, 95% CI 1.019–1.156, P = 0.012) and baseline TG (odds ratio 1.012, 95% CI 1.001–1.023, P = 0.026) were retained as independent predictors for the improvement of hemoglobin A1c (HbA1c) levels. Moreover, multivariate stepwise regression analyses revealed that changes in high-density lipoprotein cholesterol (β − 0.264, 95% CI − 1.217 to 0.000, P = 0.049) and HbA1c (β 0.302, 95% CI 0.077–1.096, P = 0.025) were retained as independent predictors for changes in BMI. Increasing the dose of empagliflozin significantly ameliorated BW, BMI, GGT, TG, fasting plasma glucose and HbA1c and increased Hct in patients with T2DM. Moreover, baseline DBP and TG were independent predictors for the improvement of HbA1c. These findings may provide useful information when considering increasing the dosage of SGLT2 inhibitors in patients with T2DM who have inadequate glycemic control. UMIN Clinical Trials Registry (UMIN000041543)." @default.
• W4285492011 created "2022-07-15" @default.
• W4285492011 creator A5000849441 @default.
• W4285492011 creator A5010631611 @default.
• W4285492011 creator A5014242359 @default.
• W4285492011 creator A5031771063 @default.
• W4285492011 creator A5039152005 @default.
• W4285492011 creator A5050405126 @default.
• W4285492011 creator A5061602610 @default.
• W4285492011 creator A5067248419 @default.
• W4285492011 creator A5078453569 @default.
• W4285492011 date "2022-07-15" @default.
• W4285492011 modified "2023-10-18" @default.
• W4285492011 title "Clinical Benefit of Switching from Low-Dose to High-Dose Empagliflozin in Patients with Type 2 Diabetes" @default.
• W4285492011 cites W1714643869 @default.
• W4285492011 cites W1847388060 @default.
• W4285492011 cites W1899868128 @default.
• W4285492011 cites W2010055261 @default.
• W4285492011 cites W2017602185 @default.
• W4285492011 cites W2051243940 @default.
• W4285492011 cites W2075205049 @default.
• W4285492011 cites W2101374656 @default.
• W4285492011 cites W2113507924 @default.
• W4285492011 cites W2116404316 @default.
• W4285492011 cites W2128219379 @default.
• W4285492011 cites W2137069992 @default.
• W4285492011 cites W2137107263 @default.
• W4285492011 cites W2146264128 @default.
• W4285492011 cites W2152189242 @default.
• W4285492011 cites W2152413054 @default.
• W4285492011 cites W2165956693 @default.
• W4285492011 cites W2171471305 @default.
• W4285492011 cites W2202866687 @default.
• W4285492011 cites W2338046714 @default.
• W4285492011 cites W2424539745 @default.
• W4285492011 cites W2887583392 @default.
• W4285492011 cites W2985447821 @default.
• W4285492011 cites W3093861069 @default.
• W4285492011 cites W3200771226 @default.
• W4285492011 cites W4226098753 @default.
• W4285492011 doi "https://doi.org/10.1007/s13300-022-01296-y" @default.
• W4285492011 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35840857" @default.
• W4285492011 hasPublicationYear "2022" @default.
• W4285492011 type Work @default.
• W4285492011 citedByCount "2" @default.
• W4285492011 countsByYear W42854920112023 @default.
• W4285492011 crossrefType "journal-article" @default.
• W4285492011 hasAuthorship W4285492011A5000849441 @default.
• W4285492011 hasAuthorship W4285492011A5010631611 @default.
• W4285492011 hasAuthorship W4285492011A5014242359 @default.
• W4285492011 hasAuthorship W4285492011A5031771063 @default.
• W4285492011 hasAuthorship W4285492011A5039152005 @default.
• W4285492011 hasAuthorship W4285492011A5050405126 @default.
• W4285492011 hasAuthorship W4285492011A5061602610 @default.
• W4285492011 hasAuthorship W4285492011A5067248419 @default.
• W4285492011 hasAuthorship W4285492011A5078453569 @default.
• W4285492011 hasBestOaLocation W42854920111 @default.
• W4285492011 hasConcept C126322002 @default.
• W4285492011 hasConcept C134018914 @default.
• W4285492011 hasConcept C156957248 @default.
• W4285492011 hasConcept C2775887513 @default.
• W4285492011 hasConcept C2777180221 @default.
• W4285492011 hasConcept C2778163477 @default.
• W4285492011 hasConcept C2778913445 @default.
• W4285492011 hasConcept C2780221984 @default.
• W4285492011 hasConcept C2780473172 @default.
• W4285492011 hasConcept C2910068830 @default.
• W4285492011 hasConcept C555293320 @default.
• W4285492011 hasConcept C71924100 @default.
• W4285492011 hasConcept C90466245 @default.
• W4285492011 hasConcept C90924648 @default.
• W4285492011 hasConceptScore W4285492011C126322002 @default.
• W4285492011 hasConceptScore W4285492011C134018914 @default.
• W4285492011 hasConceptScore W4285492011C156957248 @default.
• W4285492011 hasConceptScore W4285492011C2775887513 @default.
• W4285492011 hasConceptScore W4285492011C2777180221 @default.
• W4285492011 hasConceptScore W4285492011C2778163477 @default.
• W4285492011 hasConceptScore W4285492011C2778913445 @default.
• W4285492011 hasConceptScore W4285492011C2780221984 @default.
• W4285492011 hasConceptScore W4285492011C2780473172 @default.
• W4285492011 hasConceptScore W4285492011C2910068830 @default.
• W4285492011 hasConceptScore W4285492011C555293320 @default.
• W4285492011 hasConceptScore W4285492011C71924100 @default.
• W4285492011 hasConceptScore W4285492011C90466245 @default.
• W4285492011 hasConceptScore W4285492011C90924648 @default.
• W4285492011 hasIssue "9" @default.
• W4285492011 hasLocation W42854920111 @default.
• W4285492011 hasLocation W42854920112 @default.
• W4285492011 hasLocation W42854920113 @default.
• W4285492011 hasOpenAccess W4285492011 @default.
• W4285492011 hasPrimaryLocation W42854920111 @default.
• W4285492011 hasRelatedWork W1969808273 @default.
• W4285492011 hasRelatedWork W1993873099 @default.
• W4285492011 hasRelatedWork W2013998010 @default.
• W4285492011 hasRelatedWork W2023333646 @default.
• W4285492011 hasRelatedWork W2028937980 @default.
• W4285492011 hasRelatedWork W2035484352 @default.
• W4285492011 hasRelatedWork W2162912823 @default.

• next